Investor Relations

Message from our CEO, Chikafumi Yokoyama

Opening New Paths in Regenerative Medicine with iPS Cell Technology

REPROCELL is a regenerative medicine platform company centered on induced pluripotent stem cell (iPS cell) technology. Founded in 2003 as a university spin-off from research laboratories at Kyoto University and the University of Tokyo, REPROCELL has grown alongside the development of iPS cell technology. Immediately after the birth of iPS cells at Kyoto University in 2006, we recognized their limitless potential and we were among the first in the world to launch an iPS cell business. Today, we are accelerating our operations toward establishing new treatments for intractable diseases and cancer.

Following is an overview of REPROCELL’s key strengths and growth strategy.

Our Business Stability and Growth is Built on Three Pillars

A defining feature of our management strategy is a stabilized business structure built on three pillars, rather than relying solely upon new drug development.

1. Research Support – underpinning cutting-edge global research and generating stable revenue
2. Cell Manufacturing – producing pharmaceutical grade, high quality cells
3. Regenerative Medicine Product Development (new drugs) – driving our future growth

These three mutually reinforcing pillars stabilize our business foundation and create technological synergies.

Our Breakthrough Therapies for Intractable Diseases and Cancer Nearing Commercialization

Currently four major projects are underway in our new drug development pipeline, which serve as core drivers of our growth.

In particular, Stemchymal, a treatment for the intractable disease spinocerebellar degeneration – characterized by progressive loss of motor function – has entered the preparatory stage for regulatory approval applications in Japan and Taiwan. In the oncology field, we are also collaborating with Keio University (Japan), Kyoto University (Japan), and other institutions to develop two novel therapies that use patients’ own immune cells to attack cancer.

We Aim to Become the World’s No.1 Regenerative Medicine Platform Company

These developments are supported by our manufacturing bases across Japan, the United States, and Europe, as well as our proprietary technology that enables the safe creation of iPS cells without the use of viruses.

The regenerative medicine market is expected to grow to a scale of 50 trillion yen worldwide in the future. Leveraging our cutting-edge iPS cell technology, we aim to lead the global market and deliver hope to patients around the world who are awaiting new treatments.

REPROCELL will continue to take on new challenges as a top runner in the iPS cell business, contributing to the advancement of regenerative medicine, medical science, and biotechnology.

Chikafumi Yokoyama

Chief Executive Officer
REPROCELL, Inc.